BWM
ALZN icon

Baystate Wealth Management’s Alzamend Neuro ALZN Stock Holding History

Baystate Wealth Management’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$59 Buy
+1
New +$164 ﹤0.01% 1306

Other funds holding ALZN

Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

Baystate Wealth Management's ALZN Position: Q4 2023 in Review

Baystate Wealth Management opened a new position in Alzamend Neuro (ALZN) in Q4 2023: 1 share worth $59. The stake represents ﹤0.01% of the portfolio and ranks #1306 among its holdings.

14 funds tracked by Wall St. Rank hold ALZN as of Q4 2023.

  • Baystate Wealth Management held 1 share of Alzamend Neuro worth $59 as of Q4 2023.
  • Alzamend Neuro was a new Baystate Wealth Management position in Q4 2023.
  • Alzamend Neuro made up ﹤0.01% of Baystate Wealth Management's portfolio in Q4 2023, its #1306 holding.
  • 14 funds tracked by Wall St. Rank held Alzamend Neuro as of Q4 2023.

Based on Baystate Wealth Management's 13F filing for Q4 2023, filed 29 Jan 2024.